Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | FASN | P49327 | 4/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 7/20 | 0.37 |
| ▸ | JAK1 | P23458 | 6/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556522 | 0.88 | ACACB (0.42) | CDK1ACACBHPGDFASNSLC6A9 | |
| SCHEMBL7533942 | 0.84 | ANO1 (0.50) | ACACBHPGDFASNF10JAK2 | |
| SCHEMBL7566297 | 0.82 | F10 (0.48) | HPGDF10ALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL7565526 | 0.82 | F10 (0.47) | HPGDF10ALDH1A1LMNAHTT | |
| SCHEMBL6554507 | 0.79 | ACACB (0.46) | CDK1ACACBHPGDFASNCCKBR | |
| SCHEMBL6556808 | 0.78 | ACACB (0.53) | ACACBHPGDFASNCCKBRSLC6A9 | |
| SCHEMBL6571797 | 0.76 | ALDH1A1 (0.53) | ACACBHPGDFASNF10JAK2 | |
| SCHEMBL5885759 | 0.75 | ACACB (0.48) | CDK1ACACBHPGDFASNCCKBR | |
| SCHEMBL5091241 | 0.74 | ALDH1A1 (0.45) | ACACBALDH1A1LMNA | |
| SCHEMBL5885749 | 0.73 | ACACB (0.48) | ACACBCCKBRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | CDK1 1663/4885ACACB 2861/4885HPGD 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.